(FDA, por sus siglas en ingls) aprob Mounjaro (tirzepatida) inyectable, el nuevo agonista del receptor del GIP ( polipptido insulinotrpico dependiente de glucosa ) y del GLP-1 (pptido-1 similar al glucagn), para aplicar una vez a la semana, de Eli Lilly and Company (NYSE: LLY), indicado junto con dieta y ejercicio para mejorar el control glucmico en adultos con diabetes tipo 2
Studies on similar medications show no impact on contraceptive hormones, which suggests tirzepatide is likely safe to use with birth control
PMID: 22537212 | DOI: 10.1111/j.1753-4887.2012.00476.x [21] Machowetz A, Poulsen HE, Gruendel S, et al
The internal resistance will rise as the cell ages
Disordered eating and eating disorders can affect anyone, regardless of gender identity, race, age, socioeconomic status, or other identities
The diagnostic description of such features may provide valuable feedback and reassurance to the clinician